28228055|t|Increased Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in General Trauma Patients
28228055|a|To review the evidence regarding increased enoxaparin dosing for venous thromboembolism (VTE) prophylaxis in the general trauma patient population. A search of MEDLINE databases (1946 to October 2016) was conducted using the search terms enoxaparin, thromboembolism prophylaxis, venous thromboembolism, trauma, anti-factor Xa, and weight -based dosing. Additional references were identified from a review of literature citations. Search results were limited to English-language studies conducted in humans. Trials that included only obese patients or nontrauma patients were excluded. A total of 7 trials (958 patients) explored the use of increased dosing of enoxaparin for VTE prophylaxis in trauma patients. Patients were divided by enoxaparin dosing strategies: standard dosing of 30 mg twice daily (BID; n = 509), higher initial dosing regimen (n = 216), or dosing based on anti-FXa level adjustments (n = 233). The majority of the 42 total VTE events (64.3%) occurred in the standard dosing regimen. Within each group, VTE was reported in 5.3% of patients in the standard dosing group, 3.2% in the higher initial dosing group, and 4% in the anti-FXa adjustment group. Initial subtherapeutic anti-FXa levels occurred in 33% to 92% of standard dose patients and 9% to 39% of higher initial dose patients. The average weight -based dose required to achieve a therapeutic level ranged between 0.43 and 0.54 mg/kg/ dose BID. The overall rate of bleeding was low, with 3 incidents (0.37%) reported. Standard - dose enoxaparin prophylaxis may not be optimal for the general trauma patient population. Weight -based enoxaparin dosing (0.5 mg/kg/ dose BID) is an option in trauma patients considered to be at a lower risk of bleeding complications.
28228055	0	9	Increased	T081	C0205217
28228055	10	20	Enoxaparin	T109,T121	C0206460
28228055	21	27	Dosing	T081	C0178602
28228055	32	66	Venous Thromboembolism Prophylaxis	T061	C0199242
28228055	78	84	Trauma	T037	C3714660
28228055	85	93	Patients	T101	C0030705
28228055	97	103	review	T080	C1704362
28228055	108	116	evidence	T078	C3887511
28228055	127	136	increased	T081	C0205217
28228055	137	147	enoxaparin	T109,T121	C0206460
28228055	148	154	dosing	T081	C0178602
28228055	159	199	venous thromboembolism (VTE) prophylaxis	T061	C0199242
28228055	215	221	trauma	T037	C3714660
28228055	222	229	patient	T101	C0030705
28228055	230	240	population	T098	C1257890
28228055	244	250	search	T052	C1706202
28228055	254	271	MEDLINE databases	T170	C0025141
28228055	319	325	search	T052	C1706202
28228055	326	331	terms	T078	C1705313
28228055	332	342	enoxaparin	T109,T121	C0206460
28228055	344	371	thromboembolism prophylaxis	T061	C0199242
28228055	373	395	venous thromboembolism	T047	C1861172
28228055	397	403	trauma	T037	C3714660
28228055	405	419	anti-factor Xa	T116,T129	C0443793
28228055	425	431	weight	T081	C0043100
28228055	439	445	dosing	T081	C0178602
28228055	492	512	review of literature	T170	C0282441
28228055	513	522	citations	T170	C0552371
28228055	524	530	Search	T052	C1706202
28228055	531	538	results	T169	C1274040
28228055	555	571	English-language	T171	C0376245
28228055	572	579	studies	T062	C2603343
28228055	593	599	humans	T016	C0086418
28228055	601	607	Trials	T062	C0008976
28228055	627	632	obese	T047	C0028754
28228055	633	641	patients	T101	C0030705
28228055	645	663	nontrauma patients	T101	C0030705
28228055	669	677	excluded	T052	C2828389
28228055	692	698	trials	T062	C0008976
28228055	704	712	patients	T101	C0030705
28228055	734	743	increased	T081	C0205217
28228055	744	750	dosing	T081	C0178602
28228055	754	764	enoxaparin	T109,T121	C0206460
28228055	769	784	VTE prophylaxis	T061	C0199242
28228055	788	794	trauma	T037	C3714660
28228055	795	803	patients	T101	C0030705
28228055	805	813	Patients	T101	C0030705
28228055	830	840	enoxaparin	T109,T121	C0206460
28228055	841	847	dosing	T081	C0178602
28228055	860	868	standard	T080	C1442989
28228055	869	875	dosing	T081	C0178602
28228055	885	896	twice daily	T079	C0585361
28228055	898	901	BID	T079	C0585361
28228055	928	934	dosing	T081	C0178602
28228055	935	942	regimen	T061	C0040808
28228055	957	963	dosing	T081	C0178602
28228055	973	987	anti-FXa level	T034	C1318056
28228055	988	999	adjustments	T061	C2945673
28228055	1040	1043	VTE	T047	C1861172
28228055	1044	1050	events	T051	C0441471
28228055	1075	1083	standard	T080	C1442989
28228055	1084	1090	dosing	T081	C0178602
28228055	1091	1098	regimen	T061	C0040808
28228055	1112	1117	group	T101	C0030705
28228055	1119	1122	VTE	T047	C1861172
28228055	1147	1155	patients	T101	C0030705
28228055	1163	1171	standard	T080	C1442989
28228055	1172	1178	dosing	T081	C0178602
28228055	1179	1184	group	T101	C0030705
28228055	1213	1219	dosing	T081	C0178602
28228055	1220	1225	group	T101	C0030705
28228055	1241	1249	anti-FXa	T116,T129	C0443793
28228055	1250	1260	adjustment	T061	C2945673
28228055	1261	1266	group	T101	C0030705
28228055	1276	1290	subtherapeutic	T169	C0302350
28228055	1291	1306	anti-FXa levels	T034	C1318056
28228055	1333	1341	standard	T080	C1442989
28228055	1342	1346	dose	T081	C0178602
28228055	1347	1355	patients	T101	C0030705
28228055	1388	1392	dose	T081	C0178602
28228055	1393	1401	patients	T101	C0030705
28228055	1415	1421	weight	T081	C0043100
28228055	1429	1433	dose	T081	C0178602
28228055	1456	1473	therapeutic level	T034	C0580398
28228055	1510	1514	dose	T081	C0178602
28228055	1515	1518	BID	T079	C0585361
28228055	1532	1536	rate	T081	C1521828
28228055	1540	1548	bleeding	T046	C0019080
28228055	1553	1556	low	T080	C0205251
28228055	1593	1601	Standard	T080	C1442989
28228055	1604	1608	dose	T081	C0178602
28228055	1609	1619	enoxaparin	T109,T121	C0206460
28228055	1620	1631	prophylaxis	T061	C0199242
28228055	1667	1673	trauma	T037	C3714660
28228055	1674	1681	patient	T101	C0030705
28228055	1682	1692	population	T098	C1257890
28228055	1694	1700	Weight	T081	C0043100
28228055	1708	1718	enoxaparin	T109,T121	C0206460
28228055	1719	1725	dosing	T081	C0178602
28228055	1738	1742	dose	T081	C0178602
28228055	1743	1746	BID	T079	C0585361
28228055	1764	1770	trauma	T037	C3714660
28228055	1771	1779	patients	T101	C0030705
28228055	1802	1807	lower	T080	C0205251
28228055	1808	1812	risk	T078	C0035647
28228055	1816	1824	bleeding	T046	C0019080
28228055	1825	1838	complications	T046	C0009566